
Sanjal H Desai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6172317/publications.pdf Version: 2024-02-01



SANIAL H DESAL

#	Article	IF	CITATIONS
1	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer Journal, 2022, 12, 78.	2.8	1
2	Clearance of Hepatitis C Virus (HCV) Is Associated With Improved Outcomes in HCV-Associated Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e185-e193.	0.2	1
3	Artificial intelligence in inflammatory bowel disease endoscopy: current landscape and the road ahead. Therapeutic Advances in Gastrointestinal Endoscopy, 2021, 14, 263177452110178.	1.2	8
4	Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. Leukemia and Lymphoma, 2021, 62, 1795-1804.	0.6	3
5	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naÃ⁻ve chronic lymphocytic leukemia: a phase 2 study. Leukemia and Lymphoma, 2021, 62, 1816-1827.	0.6	0
6	Singleâ€Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large Bâ€Cell Lymphoma. Oncologist, 2021, 26, e1660-e1663.	1.9	2
7	Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma. Oncologist, 2021, 26, e2079-e2081.	1.9	2
8	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer Journal, 2021, 11, 160.	2.8	3
9	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. Blood, 2021, 138, 878-878.	0.6	3
10	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. Blood, 2021, 138, 2508-2508.	0.6	0
11	Lymphoma survivors have an increased long-term risk of chronic kidney disease. Leukemia and Lymphoma, 2020, 61, 2923-2930.	0.6	4
12	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. Leukemia and Lymphoma, 2020, 61, 2375-2382.	0.6	16
13	DA-EPOCH-R Has Comparable Outcomes in De Novo and Transformed Diffuse Large B Cell Lymphoma. Blood, 2020, 136, 15-16.	0.6	1
14	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. Blood, 2020, 136, 47-48.	0.6	0
15	Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?. Current Oncology Reports, 2019, 21, 84.	1.8	13
16	Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors. Blood, 2019, 134, 2912-2912.	0.6	1
17	Virologic Clearance of Hepatitis C Is Associated with Improved Outcomes in African American Patients with Lymphoma. Blood, 2019, 134, 1614-1614.	0.6	1
18	Management of postâ€ŧransplant lymphoproliferative disorders. British Journal of Haematology, 2018, 182, 330-343.	1.2	63